In the version of this article initially published, the same panels were inadvertently used to show negative pSmad2/3 and periostin staining in muscle of Fbn1 C1039G/+ mice treated with TGF-β-neutralizing antibody in both the steady-state (Fig. 1a, right column, second and third rows, respectively) and muscle-regeneration (Fig. 1b, right column, third and fourth rows, respectively) experiments. In reality, these images only relate to the steady-state experiment (Fig. 1a) . The intended images for Figure 1b are provided (red, pSmad2/3 staining; green, periostin staining). As both sets of images show negative staining in neutralizing antibody-treated Fbn1
We wish to alert our readers that VX-680, the compound originally reported in the above study, is no longer available from the authors at Vertex Pharmaceuticals due to a post-publication licensing agreement with Merck. However, the compound (referred to by Merck as MK-0457) is being made available through Merck's Investigator-Initiated Studies Program (https://www.merckiisp.com). 
